Duchenne Parent Project Spain has been instrumental for the set-up of the Spanish clinical activities that focuses on testing Rimeporide in patients affected by Duchenne Muscular Dystrophy. Over the last few months, Dr Marisol Montolio Del Olmo helped EspeRare make the link with Dr. Jordi Díaz Manera from the Santa Creu i Sant Pau Hospital in Barcelona who will lead the first safety study of Rimeporide in 6 to 14 years old boys affected by Duchenne in Spain. In addition, DPP Spain is also providing administrative and funding supports for the travel and accommodation of patients and families who will be participating in this clinical trial.
Florence Porte Thomé, R&D Director of EspeRare said “Without the intervention of DPP Spain, it may not have been possible for EspeRare to open a clinical site in Spain. This partnership is a prime example of the power and importance of collaborating with patients organization to develop treatments for Duchenne Muscular Dystrophy.”
The study is now opened to recruitment in four clinical centers in Europe, the Santa Creu i Sant Pau Hospital (Barcelona, Spain), Armand Trousseau Hospital/ I-motion (Paris, France) and the San Raffaele Hospital (Milan, Italy) and soon in the Great Ormond Street Hospital (London, UK). “
For more information please visit:
-> www.clinicaltrials.gov
-> DPP Spain news release
